General Information of Drug Transporter (DT)
DT ID	DTD0278 Transporter Info
Gene Name	SLC31A1
Protein Name	High affinity copper uptake protein 1
Gene ID	1317
UniProt ID	O15431
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs10759637
Site of GPD	chr9:113262744 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Minor Allele Frequency	A=0.4908/2458 (Global)
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Platinum Compounds	N.A.	Thrombocytopenia	Genotype AC is associated with increased severity of Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.		[ 1]
Platinum Compounds	N.A.	Overall Survival	Genotype AC is associated with decreased likelihood of overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.		[ 1]
Platinum compounds	N.A.	Non-Small-Cell Lung Carcinoma	Correlated with the decreased likelihood of overall survival in patients (compare with genotypes AA + CC)		[ 1]
Platinum compounds	N.A.	Thrombocytopenia	Correlated with the increased severity of thrombocytopenia in patients (compare with genotypes AA + CC)		[ 1]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Platinum Compounds	N.A.	Overall Survival	Patients with the AA genotype and non-small cell lung cancer may have increased likelihood of overall survival in as compared to patients with the AC genotype. Other clinical and genetic factors may also influence overall survival in patients who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Thrombocytopenia	Patients with the AA genotype and non-small cell lung cancer may have increased likelihood of overall survival in as compared to patients with the AC genotype. Other clinical and genetic factors may also influence overall survival in patients who are treated with platinum compounds.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Platinum Compounds	N.A.	Overall Survival	Patients with the CC genotype and non-small cell lung cancer may have increased likelihood of overall survival in as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Thrombocytopenia	Patients with the CC genotype and non-small cell lung cancer may have increased likelihood of overall survival in as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Genetic Polymorphism	rs2233914
Site of GPD	chr9:113221260 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A
Minor Allele Frequency	A=0.2015/1009 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Platinum Compounds	N.A.	Drug Toxicity	Genotype AA is associated with decreased severity of Drug Toxicity when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 1]
Platinum Compounds	N.A.	Overall Survival	Genotype AA is associated with increased likelihood of overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 1]
Platinum compounds	N.A.	Non-Small-Cell Lung Carcinoma	Correlated with the decreased severity of drug toxicity in patients (compare with Genotypes AG + GG); Correlated with the increased likelihood of overall survival in patients (compare with genotypes AG + GG)		[ 1]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Platinum Compounds	N.A.	Drug Toxicity	Patients with the AG genotype and non-small cell lung cancer who are treated with platinum compounds may have increased likelihood of drug toxicity and decreased likelihood of overall survival as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Overall Survival	Patients with the AG genotype and non-small cell lung cancer who are treated with platinum compounds may have increased likelihood of drug toxicity and decreased likelihood of overall survival as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Platinum Compounds	N.A.	Drug Toxicity	Patients with the GG genotype and non-small cell lung cancer who are treated with platinum compounds may have increased likelihood of drug toxicity and decreased likelihood of overall survival as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Overall Survival	Patients with the GG genotype and non-small cell lung cancer who are treated with platinum compounds may have increased likelihood of drug toxicity and decreased likelihood of overall survival as compared to patients with the AA genotypes. Other clinical and genetic factors may also influence drug toxicity and likelihood of overall survival in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Genetic Polymorphism	rs4979223
Site of GPD	chr9:113219836 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>C
Minor Allele Frequency	A=0.4718/2363 (Global)
Genotype AC	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Platinum Compounds	N.A.	Overall Survival	Genotype AC is associated with decreased likelihood of overall survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.		[ 1]
Platinum Compounds	N.A.	Thrombocytopenia	Genotype AC is associated with increased severity of Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AA + CC.		[ 1]
Platinum compounds	N.A.	Non-Small-Cell Lung Carcinoma	Correlated with the decreased likelihood of overall survival in patients (compare with genotypes AA + CC)		[ 1]
Platinum compounds	N.A.	Thrombocytopenia	Correlated with the increased severity of thrombocytopenia in patients (compare with genotypes AA + CC)		[ 1]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Platinum Compounds	N.A.	Overall Survival	Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of thrombocytopenia, and increased likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.		[ 1]
Platinum Compounds	N.A.	Thrombocytopenia	Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of thrombocytopenia, and increased likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Platinum Compounds	N.A.	Overall Survival	Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of thrombocytopenia, and increased likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.		[ 1]
Platinum Compounds	N.A.	Thrombocytopenia	Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of thrombocytopenia, and increased likelihood of overall survival as compared to patients with the AC genotype. Other clinical and genetic factors may also influence severity of thrombocytopenia and overall survival in patients with non-small lung cancer.		[ 1]
Genetic Polymorphism	rs7851395
Site of GPD	chr9:113240184 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.4934/2471 (Global)
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Cisplatin	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased overall survival in patients (compare with genotypes AG + GG)		[ 2]
Carboplatin	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased overall survival in patients (compare with genotypes AG + GG)		[ 2]
Carboplatin	N.A.	Ototoxicity	Genotype AA is associated with increased overall survival when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 2]
Cisplatin	N.A.	Ototoxicity	Genotype AA is associated with increased overall survival when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 2]
Carboplatin	N.A.	Non-small Cell Lung Carcinoma	Genotype AA is associated with increased overall survival when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 2]
Cisplatin	N.A.	Non-small Cell Lung Carcinoma	Genotype AA is associated with increased overall survival when treated with carboplatin or cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotypes AG + GG.		[ 2]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Carboplatin	N.A.	Non-small Cell Lung Carcinoma	Patients with the AG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.		[ 2]
Cisplatin	N.A.	Non-small Cell Lung Carcinoma	Patients with the AG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.		[ 2]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Carboplatin	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.		[ 2]
Cisplatin	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype may have decreased overall survival when treated with carboplatin or cisplatin in people with Non-Small-Cell Lung Carcinoma as compared to patients with genotypes AA. Other genetic or clinical factors may also influence the response to carboplatin or cisplatin.		[ 2]
Genetic Polymorphism	rs10981694
Site of GPD	chr9:113224129 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>G
Minor Allele Frequency	G=0.1160/581 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Cisplatin	Drug Info	Testicular Neoplasm	Irrelevant to the likelihood of ototoxicity in patients (compare with Allele T)		[ 3]
Cisplatin	N.A.	Ototoxicity	Allele G is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele T.		[ 3]
Cisplatin	N.A.	Non-small Cell Lung Carcinoma	Allele G is not associated with likelihood of Ototoxicity when treated with cisplatin in men with Testicular Neoplasms as compared to allele T.		[ 3]
Genotypes GG + GT	Click to Show/Hide the Full List of Affected Drugs:           3 Drugs in Total
Cisplatin	Drug Info	Non-Small-Cell Lung Carcinoma	Correlated with the increased severity of ototoxicity in patients (compare with Genotype TT)		[ 4]
Cisplatin	N.A.	Ototoxicity	Genotypes GG + GT are associated with increased severity of Ototoxicity when treated with cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 4]
Cisplatin	N.A.	Non-small Cell Lung Carcinoma	Genotypes GG + GT are associated with increased severity of Ototoxicity when treated with cisplatin in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 4]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Cisplatin	N.A.	Non-small Cell Lung Carcinoma	Patients with the GG genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.		[ 4]
Genotype GT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Cisplatin	N.A.	Non-small Cell Lung Carcinoma	Patients with the GT genotype and NSCLC who are treated with cisplatin may have an increased risk of severe ototoxicity as compared to patients with the TT genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.		[ 4]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Cisplatin	N.A.	Non-small Cell Lung Carcinoma	Patients with the TT genotype and NSCLC who are treated with cisplatin may have an reduced risk of severe ototoxicity as compared to patients with the GT or GG genotype. Other genetic and clinical factors may also influence a patient's risk of cisplatin-induced ototoxicity.		[ 4]
Genetic Polymorphism	rs10817464
Site of GPD	chr9:113230217 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	T>A / T>C
Minor Allele Frequency	C=0.0946/474 (Global)
Allele T	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Platinum Compounds	N.A.	Overall Survival	Allele T is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.		[ 1]
Platinum Compounds	N.A.	Progression-free Survival	Allele T is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.		[ 1]
Platinum Compounds	N.A.	Anemia	Allele T is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.		[ 1]
Platinum Compounds	N.A.	Leukopenia	Allele T is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.		[ 1]
Platinum Compounds	N.A.	Nausea	Allele T is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.		[ 1]
Platinum Compounds	N.A.	Neutropenia	Allele T is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.		[ 1]
Platinum Compounds	N.A.	Thrombocytopenia	Allele T is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.		[ 1]
Platinum Compounds	N.A.	Vomiting	Allele T is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele C.		[ 1]
Platinum compounds	N.A.	Non-Small-Cell Lung Carcinoma	Irrelevant to the likelihood of overall survival and progression-free survival in patients (compare with allele C)		[ 1]
Genotypes CC + CT	Click to Show/Hide the Full List of Affected Drugs:           9 Drugs in Total
Platinum Compounds	N.A.	Drug Toxicity	Genotypes CC + CT is associated with increased severity of Drug Toxicity, Hematologic Diseases, Leukopenia and Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 1]
Platinum Compounds	N.A.	Hematologic Disorder	Genotypes CC + CT is associated with increased severity of Drug Toxicity, Hematologic Diseases, Leukopenia and Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 1]
Platinum Compounds	N.A.	Leukopenia	Genotypes CC + CT is associated with increased severity of Drug Toxicity, Hematologic Diseases, Leukopenia and Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 1]
Platinum Compounds	N.A.	Thrombocytopenia	Genotypes CC + CT is associated with increased severity of Drug Toxicity, Hematologic Diseases, Leukopenia and Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 1]
Platinum Compounds	N.A.	Anemia	Genotypes CC + CT is associated with increased severity of Drug Toxicity, Hematologic Diseases, Leukopenia and Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 1]
Platinum Compounds	N.A.	Nausea	Genotypes CC + CT is associated with increased severity of Drug Toxicity, Hematologic Diseases, Leukopenia and Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 1]
Platinum Compounds	N.A.	Neutropenia	Genotypes CC + CT is associated with increased severity of Drug Toxicity, Hematologic Diseases, Leukopenia and Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 1]
Platinum Compounds	N.A.	Vomiting	Genotypes CC + CT is associated with increased severity of Drug Toxicity, Hematologic Diseases, Leukopenia and Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype TT.		[ 1]
Platinum compounds	N.A.	Non-Small-Cell Lung Carcinoma	Correlated with the increased severity of drug toxicity, hematologic diseases, leukopenia and thrombocytopenia in patients (compare with Genotype TT)		[ 1]
Genotype CC	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Platinum Compounds	N.A.	Anemia	Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Leukopenia	Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Nausea	Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Neutropenia	Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Thrombocytopenia	Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Vomiting	Patients with the CC genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Genotype CT	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Platinum Compounds	N.A.	Anemia	Patients with the CT genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Leukopenia	Patients with the CT genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Nausea	Patients with the CT genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Neutropenia	Patients with the CT genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Thrombocytopenia	Patients with the CT genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Vomiting	Patients with the CT genotype and non-small cell lung cancer who are treated with platinum compounds may have increased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the TT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Genotype TT	Click to Show/Hide the Full List of Affected Drugs:           6 Drugs in Total
Platinum Compounds	N.A.	Anemia	Patients with the TT genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Leukopenia	Patients with the TT genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Nausea	Patients with the TT genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Neutropenia	Patients with the TT genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Thrombocytopenia	Patients with the TT genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Platinum Compounds	N.A.	Vomiting	Patients with the TT genotype and non-small cell lung cancer who are treated with platinum compounds may have decreased severity of drug toxicity (nausea, vomiting) and hematologic toxicity (leukopenia, neutropenia, anemia, and thrombocytopenia) as compared to patients with the CC or CT genotype. Other clinical and genetic factors may also influence toxicity in patients with non-small cell lung cancer who are treated with platinum compounds.		[ 1]
Genetic Polymorphism	rs4978536
Site of GPD	chr9:113220123 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	G=0.3051/1528 (Global)
Allele A	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Platinum Compounds	N.A.	Overall Survival	Allele A is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.		[ 1]
Platinum Compounds	N.A.	Progression-free Survival	Allele A is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele G.		[ 1]
Genotypes AG + GG	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Platinum Compounds	N.A.	Thrombocytopenia	Genotypes AG + GG is associated with increased severity of Thrombocytopenia when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to genotype AA.		[ 1]
Platinum compounds	N.A.	Non-Small-Cell Lung Carcinoma	Correlated with the increased severity of thrombocytopenia in patients (compare with genotype AA)		[ 1]
Genotype AA	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Platinum Compounds	N.A.	Thrombocytopenia	Patients with the AA genotype and non-small cell lung cancer who are treated with platinum compounds may have a decreased severity of thrombocytopenia as compared to patients with the AG or GG genotypes. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.		[ 1]
Genotype AG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Platinum Compounds	N.A.	Thrombocytopenia	Patients with the AG genotype and non-small cell lung cancer who are treated with platinum compounds may have a increased severity of thrombocytopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.		[ 1]
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           1 Drugs in Total
Platinum Compounds	N.A.	Thrombocytopenia	Patients with the GG genotype and non-small cell lung cancer who are treated with platinum compounds may have a increased severity of thrombocytopenia as compared to patients with the AA genotype. Other clinical and genetic factors may also influence risk of thrombocytopenia in patients with non-small lung cancer who are treated with platinum compounds.		[ 1]
Genetic Polymorphism	rs10817465
Site of GPD	chr9:113243503 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	C>G / C>T
Minor Allele Frequency	C=0.3750/742 (Global)
Allele C	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Platinum Compounds	N.A.	Overall Survival	Allele C is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.		[ 1]
Platinum Compounds	N.A.	Progression-free Survival	Allele C is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele T.		[ 1]
Genetic Polymorphism	rs10513202
Site of GPD	chr9:113262679 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	A>G
Minor Allele Frequency	A=0.8740/1729 (Global)
Allele G	Click to Show/Hide the Full List of Affected Drugs:           2 Drugs in Total
Platinum Compounds	N.A.	Overall Survival	Allele G is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.		[ 1]
Platinum Compounds	N.A.	Progression-free Survival	Allele G is not associated with likelihood of overall survival and progression-free survival when treated with Platinum compounds in people with Carcinoma, Non-Small-Cell Lung as compared to allele A.		[ 1]
References
1	Genetic polymorphism of SLC31A1 is associated with clinical outcomes of platinum-based chemotherapy in non-small-cell lung cancer patients through modulating microRNA-mediated regulation. Oncotarget. 2018 May 8;9(35):23860-23877.
2	Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients. Clin Exp Pharmacol Physiol. 2012 Sep;39(9):786-92.
3	Association Between SLC16A5 Genetic Variation and Cisplatin-Induced Ototoxic Effects in Adult Patients With Testicular Cancer. JAMA Oncol. 2017 Nov 1;3(11):1558-1562.
4	Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer. 2012 Aug;77(2):438-42.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.